null

null

null

null

null

null

null

null

null

0.39x Total Debt / Equity (Conservative)

Moderate; ~$50M term loan at variable rates means 200bps rise adds ~$1M annual interest expense, manageable vs. ~$180M revenue

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-source human tissue procurement via licensed tissue banks; regulatory-constrained US donor network creates geographic concentration risk

Minimal; ~95% of revenue is US-derived, limiting sovereign currency devaluation exposure to negligible levels internationally

Predominantly US-only operations; international revenue <5% of total, primarily limited EU/Canada exposure with immaterial FX devaluation risk

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; AxoGen relies on a limited number of FDA-regulated human tissue suppliers with no commodity substitutes, representing critical non-substitutable input

Cloud disruption risk is low-moderate; core operations are manufacturing and surgical logistics, not cloud-native SaaS, though CRM/ERP disruption would cause weeks of sales friction

Secondary digital tools (Salesforce, ERP) could be migrated within 60-90 days; no proprietary cloud-dependent revenue generation model exists

Low API coupling risk; no material third-party API dependencies in revenue-generating workflow; switching cost is institutional, not technical

Not applicable; revenue model is commercial medical device/tissue product sales, not an investment contract—Howey Test inapplicable

Very High

Low-moderate; HIPAA is primary compliance driver; limited EU patient data exposure; CCPA applies to US commercial contacts only, manageable compliance burden

Low-moderate; AxoGen holds ~70% US peripheral nerve repair market share, creating potential monopolization scrutiny as market grows and pricing power increases

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~90% transactional (per-procedure product sales); ~10% recurring via institutional accounts and consignment inventory agreements with hospitals

Per-unit surgical consumable sales (nerve grafts, connectors, conduits) billed per procedure; no subscription or SaaS component

Premium pricing (~$1,000–$5,000 per graft unit) supported by clinical differentiation; vulnerable to GPO renegotiation pressure and hospital budget freezes

7/10; strong clinical outcomes data supports premium, but hospital value analysis committees and GPO contracts limit unilateral price increases above ~3-5% annually

74.3% Gross Margin (Premium (>60%))

Low free-rider risk; product is consumable and procedure-specific; no open-source or generic equivalent currently FDA-cleared for comparable indications

Headcount-linear; direct sales force drives adoption surgeon-by-surgeon; doubling revenue likely requires ~70-80% proportional headcount increase in sales

High marginal cost; each new territory requires dedicated clinical specialist; manufacturing scale provides some COGS leverage but SG&A scales nearly linearly

Not applicable; AxoGen operates a direct commercial model, not a franchise structure

At 10x scale, CAC efficiency improves modestly via brand recognition, but surgeon-level education requirement keeps CAC structurally high (~$15,000–$25,000 per new surgeon)

Weak network effects; clinical outcome data accumulation creates modest evidence moat, but no direct user-to-user network dynamic exists in the business model

-6.6% Return on Assets (Negative equity)

Tier 2 (moderate resilience); peripheral nerve repair is often elective-reconstructive, subject to hospital capex deferral but protected by trauma and cancer indications

Surgeons and hospital systems performing peripheral nerve repair; top 20% of high-volume surgeons likely represent ~50%+ of revenue—moderate concentration risk

Hospital GPO purchasing consortia (e.g., Vizient, Premier); GPO contract loss could impact institutional access for a significant revenue block simultaneously

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

1.7% CapEx / Revenue (Low-CapEx Asset-Light)

0000805928

AXGN